In 2017, the Pancreatic Cancer Action Network will invest $12.8 million in innovative pancreatic cancer research, a 33 percent increase over last year. This investment includes both competitive, peer-reviewed Research Grants and the organization's internal research initiatives.
To that end, the network has issued an RFP for its Precision Medicine Targeted Grant program. Grants of up to $1 million total (direct, plus a maximum of 20 percent indirect costs) will be awarded for research projects relevant to pancreatic ductal adenocarcinoma, including treatments for respectable, locally advanced, metastatic, or recurrent disease.
Applications from academic institutions or for-profit biotechnology or pharmaceutical firms will be accepted. There are expectations for reasonable cost- and profit-sharing in contracts with for-profit agencies. The principal investigator must have a doctoral degree (Ph.D., M.D., D.O., Pharm.D. or equivalent) in a biomedical science or in a field applicable to health science research.
For complete program guidelines and application instructions, see the PANCAN website.